Selected Publications*

How to implement new diagnostic products in low-resource settings: an end-to-end framework. Mugambi ML, Peter T, Martins SF, Giachetti C. BJM Global Health, 3:e000914 (2018).

Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. Reid JL, Wright TC Jr, Stoler MH, Cuzick J, Castle PE, Dockter J, Getman D, Giachetti C. Am J Clin Pathol. 144(3): 473-83 (2015).

APTIMA HPV Assay Performance in Women with ASC-US Pap Results. Stoler M, Wright T, Cuzick J, Dockter J, Reid J, Getman D, Giachetti C. Am J Obstet Gynecol. 208:144.e1-8(2013).

Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. J Clin Virol. Jul;45 Suppl 1:S55-61(2009).

Incidence of transaminitis among HIV-infected patients with occult hepatitis B. Lo Re V 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, Giachetti C, Dorey-Stein Z, Frank I, Strom BL, Gross R. J Clin Virol. Sep;43(1):32-36(2008).

A Cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Castle PE, Dockter, J, Giachetti C, Garcia FAR, McCormick MK, Mitchell AL, Holladay EB, Kolk DP. Clin Cancer Res. 13(9):2599-2605(2007).

Performance Evaluation of the PROCLEIX West Nile Virus Assay on Semi-Automated and Automated Systems. Linnen JM, Deras ML, Cline J, Wu W, Broulik AS, Cory RE, Knight JL, Cass MMJ, Collins CS, Giachetti C. J Med Virol. 79:1422-1430(2007).

Dynamics of viremia in early hepatitis C virus infection. Glynn S, Wright D, Kleinman S, Hirschkom D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch M. Transfusion. 45.994-1002(2005).

The risk of Hepatitis B virus infection by transfusion in Kumasi, Ghana. Allain JP, Candotti D, Soldan K, Sarkodie F, Phelps B, Giachetti C, Yeboah F, Anokwa M, Owusu-Ofor S, Opare-Sem O. Blood. 101,2419-2425(2003).

Highly Sensitive Multiplex Assay for Detection of HIV-1 and HCV RNA. Giachetti C, Linnen JM, Kolk DP, Dockter J, McCormick MK, Ho-Sing-Loy M, Park M, Gillotte-Taylor K, Mimms L, McDonough SH. J Clin Microbiol. 40:1761-1766(2002).

Evaluation of Performance of the Gen-Probe HIV-1 Viral Load Assay Using Primary Subtype A, C and D Isolates from Kenya. Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff D, Jagodzinski LL, Michael NL, Nduati R, Bwasyo J, Kreiss JK, Overbaugh J. J Clin Microbiol. 38:2688-2695(2000).

Increased Oligonucleotide Permeability in Keratinocytes of Artificial Skin Correlates with Differentiation and Altered Membrane Function. Giachetti C, Chin D. J Invest Dermatol. 3:412-418(1996).

High Frequency of Single Base  Transitions, and Extreme Frequency of Precise, Multiple-Base Reversion Mutations in Poliovirus.  de la Torre JC*, Giachetti C*,  Semler BL, Holland JJ. Proc Natl Acad SCI USA 89:2531-2535.(1992) (*) The first two authors contributed equally to the work presented in this paper.

cis-Acting Lesions Targeted to the Hydrophobic Domain of a Poliovirus Membrane Protein Involved in RNA Replication.  Giachetti C, Hwang S-S, Semler BL. J Clin Virol. 66:6045-6057(1992).

Continuing Evolution of Virus and Defective Interfering Particles and of Viral Genome Sequences During Undiluted Passages: Virus Mutants Exhibiting Nearly Complete Resistance to Formerly Dominant Defective Interfering particles. DePolo NJ, Giachetti C, Holland JJ.  J Clin Virol. 61:454-464(1987).

*Complete list of publications: https://www.researchgate.net/profile/Cristina_Giachetti/publications

Issued US Patents

Arnold, L., Reynolds. M.A., and Giachetti, C., Lebedev A.V.  Chimeric Oligonucleoside Compounds. Genta May 2000: US Patent Number 6060456

Arnold, L., Reynolds. M.A., and Giachetti, C.  Method for Inhibiting RNA Translation using Chimeric Oligonucleoside Compounds. Genta July 2001: US Patent Number 6262036  

Bee, G.G.; Yang, Y.; Kolk, D.K.; Giachetti, C.; McDonough, S.H. Detection of HIV-1 by Nucleic Acid Amplification. Gen-Probe September 2003: U.S. Patent Number 6623920Bee,

G.G.; Yang, Y.; Kolk, D.K.; Giachetti, C.; McDonough, S.H. Detection of HIV-1 by Nucleic Acid Amplification. Gen-Probe August 2006: U.S. Patent Number 7097979

Bee, G.G.; Yang, Y.; Kolk, D.K.; Giachetti, C.; McDonough, S.H. Detection of HIV-1 by Nucleic Acid Amplification. Gen-Probe September 2008: U.S. Patent Number 7425417

Bee, G.G.; Yang, Y.; Kolk, D.K.; Giachetti, C.; McDonough, S.H. Detection of HIV-1 by Nucleic Acid Amplification. Gen-Probe May 2010: U.S. Patent Number 7723040

Product Awards

2011 CONNECT’s Otterson Award for the Procleix Assays which were recognized as “Technology/product(s) developed in San Diego that have had a worldwide impact”

2004 National Medal of Technology and Innovation for “The development and commercialization of new blood- testing technologies and systems for the direct detection of viral infections, including direct identification of West Nile Virus and simultaneous identification of HIV-1 and Hepatitis C virus in plasma of human blood and organ donors prior to transfusion”

2003 Frost & Sullivan’s 2003 Clinical Diagnostics Technology Innovation of the Year Award for outstanding performance and achievements in the healthcare industry: “Gen-Probe has successfully developed and introduced a pioneering platform to the blood-banking industry, making a noteworthy impact on the market and society”

2002 CONNECT’s Award for the PROCLEIX® HIV-1/HCV Assay as the "Most Innovative New Product Life Sciences"

Award of $1.0 M and supplemental award of $7.6M from NHLBI to Gen-Probe to develop a nucleic acid test to screen donated blood, organs and cadaveric tissue donors for West Nile Virus (WNV), and to pursue clinical studies and US regulatory approval, 2002-2003

Award of $7.6 M from NHLBI to Gen-Probe to develop a multiplex nucleic acid test to screen donated blood, organs and cadaveric tissue donors for HIV-1, HBV and HCV, 1998

Award of $4.3 M from NHLB to Gen-Probe to develop a nucleic acid test to screen donated blood for human immunodeficiency virus type 2 (HIV-2) and hepatitis B virus (HBV), 1998

Award of $7.7M from National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to Gen-Probe to develop a nucleic acid test to screen donated blood for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV), 1996